Systemic therapy of brain metastases: non–small cell lung cancer, breast cancer, and melanoma
Tóm tắt
Từ khóa
Tài liệu tham khảo
Tabouret, 2012, Recent trends in epidemiology of brain metastases: an overview, Anticancer Res, 32, 4655
Eichler, 2011, The biology of brain metastases-translation to new therapies, Nat Rev Clin Oncol, 8, 344, 10.1038/nrclinonc.2011.58
Brown PD Asher AL Ballman KV . A phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases. J Clin Oncol. 2015;33 suppl):abstr LBA4.
Yamamoto M Serizawa T Higuchi Y . A multi-institutional prospective observational study of stereotactic radiosurgery (SRS) for patients with multiple brain metastases (BMs): updated results of the JLGK0901 study—long-term results of irradiation-related complications and neurocognitive function (NCF). J Clin Oncol. 2015;33 (suppl):abstr 2020.
Tsao, 2003, Supportive care management of brain metastases: what is known and what we need to know. Conference proceedings of the National Cancer Institute of Canada (NCIC) Workshop on Symptom Control in Radiation Oncology, Clin Oncol (R Coll Radiol), 15, 429, 10.1016/S0936-6555(03)00220-6
Goldberg SB Gettinger SN Mahajan A . Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases. J Clin Oncol. 2015;33 (suppl):abstr 8035.
Yu HA Sima CS Reales D . A phase I study of twice weekly pulse dose and daily low dose erlotinib as initial treatment for patients (pts) with EGFR-mutant lung cancers. J Clin Oncol. 2015;33 (suppl):abstr 8017.
Jackman DM Mach SL Heng JC . Pulsed dosing of erlotinib for central nervous system progression in EGFR-mutant non-small cell lung cancer [abstr 8116]. J Clin Oncol. 2013;31(suppl).
Bordi, 2014, Overcoming T790M-driven acquired resistance to EGFR-TKIs in NSCLC with afatinib: a case report, Tumori, 100, e20
Kim D-W Yang JC-H Chen K . AZD3759, an EGFR inhibitor with blood brain barrier (BBB) penetration for the treatment of non-small cell lung cancer (NSCLC) with brain metastasis (BM): Preclinical evidence and clinical cases. J Clin Oncol. 2015;33(suppl):abstr 8016.
Tagrisso (osimertinib) tablet, for oral use. Available at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo. Accessed January 11, 2016.
Varga, 2015, Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvement, Eur J Cancer, 51, S598, 10.1016/S0959-8049(16)31654-9
Ahn, 2015, AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: data from phase II studies, Eur J Cancer, 51, S625, 10.1016/S0959-8049(16)31724-5
Akimoto, 1999, Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas, Clin Cancer Res, 5, 2884
Chinnaiyan, 2005, Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva), Cancer Res, 65, 3328, 10.1158/0008-5472.CAN-04-3547
Zykadia (ceritinib) capsules for oral use. Prescribing Information. Available at http://www.pharma.us.novartis.com/product/pi/pdf/zykadia.pdf Accessed August 31, 2015.
ClinicalTrials.gov. Available at https://clinicaltrials.gov/. Accessed May 28, 2016.
Gandhi L Shaw A Gadgeel SM . A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK+ non-small-cell lung cancer (NSCLC) U.S./Canadian population who had progressed on crizotinib (NP28761). J Clin Oncol. 2015;33(suppl):abstr 8019.
Ou S-HI Ahn JS Petris LD . Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: an open-label, single-arm, global phase 2 study (NP28673). J Clin Oncol. 2015;33(suppl):abstr 8008.
Alecensa (alectinib) capsules, for oral use. Prescribing Information. Available at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo. Accessed January 8, 2016.
Gettinger SN Bazhenova L Salgia R . Brigatinib (AP26113) efficacy and safety in ALK+ NSCLC: phase 1/2 trial results. Presented at 16th World Conference on Lung Cancer; September 9, 2015; Denver, CO.
Bauer TM Shaw AT Solomon B . Phase I/II study of PF-06463922, an ALK/ROS1 tyrosine kinase inhibitor, in patients with advanced non-small-cell lung cancer harboring specific molecular alterations. J Clin Oncol. 2015;33(suppl):abstr TPS2620.
Shaw AT Bauer TM Felip E . Clinical activity and safety of PF-06463922 from a dose escalation study in patients with advanced ALK+ or ROS1+ NSCLC. J Clin Oncol. 2015;33(suppl):abstr 8018.
Kumar, 2012, Application of microarray in breast cancer: an overview, J Pharm Bioallied Sci, 4, 21, 10.4103/0975-7406.92726
COSMIC, catalogue of somatic mutations in cancer. Available at http://cancer.sanger.ac.uk/cosmic/browse/tissue#sn=breast&ss=NS&hn=carcinoma. Accessed January 15, 2016.
Cho, 2015, The use of stereotactic radiosurgery for brain metastases from breast cancer: who benefits most?, Breast Cancer Res Treat, 149, 743, 10.1007/s10549-014-3242-x
Gradishar, 2014, Breast cancer version 3.2014, J Natl Compr Canc Netw, 12, 542, 10.6004/jnccn.2014.0058
Siegelmann-Danieli, 2003, Complete response of brain metastases originating in breast cancer to capecitabine therapy, Isr Med Assoc J, 5, 833
Awada A Colomer R Bondarenko I . Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib + paclitaxel vs trastuzumab + paclitaxel as first-line treatment for HER2+ metastatic breast cancer (NEfERTT). J Clin Oncol. 2015;33(suppl):abstr 610.
Saleem, 2015, Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer, EJNMMI Res, 5, 30, 10.1186/s13550-015-0103-5
Alés-Martínez JE Filipovich E Llano JLG Viro JC Sánchez-Escribano R . Dual anti-HER2 therapy (lapatinib and trastuzumab) plus capecitabine is a very effective and well-tolerated regimen (CLT) in metastatic HER2-positive breast cancer patients. J Clin Oncol. 2014;32(suppl):abstr e11513.
Bergen, 2015, Breast cancer brain metastases responding to lapatinib plus capecitabine as second-line primary systemic therapy, Anticancer Drugs, 26, 579, 10.1097/CAD.0000000000000217
Ferrario C Welch S Chaves JM . ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets). J Clin Oncol. 2015;33(suppl):abstr 612.
Nanda R Chow LQ Dees EC . A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer [abstract S1-09]. Available at https://www.sabcs.org/About/Past-Symposia. Accessed March 11, 2016.
Salvati, 1993, Prolonged stabilization of multiple and single brain metastases from breast cancer with tamoxifen. Report of three cases, Tumori, 79, 359, 10.1177/030089169307900516
Madhup, 2006, Letrozole for brain and scalp metastases from breast cancer–a case report, Breast, 15, 440, 10.1016/j.breast.2005.07.006
Cassier, 2008, A phase 2 trial of whole-brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancer, Cancer, 113, 2532, 10.1002/cncr.23858
Budman, 1978, The current causes of death in patients with malignant melanoma, Eur J Cancer, 14, 327, 10.1016/0014-2964(78)90201-3
Zacest, 2002, Surgical management of cerebral metastases from melanoma: outcome in 147 patients treated at a single institution over two decades, J Neurosurg, 96, 552, 10.3171/jns.2002.96.3.0552
Kluger HM Goldberg SB Sznol M . Safety and activity of pembrolizumab in melanoma patients with untreated brain metastases. J Clin Oncol. 2015;33(suppl):abstr 9009.
Sloan, 2009, Diagnosis and treatment of melanoma brain metastasis: a literature review, Cancer Control, 16, 248, 10.1177/107327480901600307
Long GV Margolin KA . Multidisciplinary approach to brain metastasis from melanoma: the emerging role of systemic therapies. Am Soc Clin Oncol Educ Book. 2013:393–398.
Sørensen, 1988, Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis, J Clin Oncol, 6, 1474, 10.1200/JCO.1988.6.9.1474
Quan, 2004, Brain metastases in small cell lung cancer, Oncology, 18, 961
Gummadi, 2015, Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases, Melanoma Res, 25, 75, 10.1097/CMR.0000000000000133
Deng, 2014, The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancer, Mol Clin Oncol, 2, 116, 10.3892/mco.2013.190
Togashi, 2010, Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer, J Thorac Oncol, 5, 950, 10.1097/JTO.0b013e3181e2138b
Wind, 2014, Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir, Clin Drug Investig, 34, 173, 10.1007/s40261-013-0161-2
Zelboraf (vemurafenib) [US package insert]. South San Francisco, CA: Genentech;2014.
Tafinlar (dabrafenib) [US package insert]. Research Triangle Park, NC: GlaxoSmithKline;2014.
Shaw AT Mehra R Tan DSW . Evaluation of ceritinib-treated patients with anaplastic lymphoma kinase rearranged (ALK+) non-small cell lung cancer (NSCLC) and brain metastases in the ASCEND-1 study [abstract 1293P]. Presented at the European Society For Medical Oncology Annual Meeting; September 26–30, 2014; Madrid, Spain.
Mok T Spigel D Felip E . ASCEND-2: a single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). J Clin Oncol. 2015;33(suppl):abstr 8059.
Felip E Orlov S Park K . ASCEND-3: a single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33(suppl):abstr 8060.
Camidge DR Bazhenova L Salgia R . Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non–small cell lung cancer (NSCLC). J Clin Oncol. 2015;33(suppl):abstr 8062.
Gettinger SN Bazhenova L Salgia R . Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC). J Clin Oncol. 2014;32 (suppl):abstr 8047.